Merck Financials Remain On Track, Despite Generic Cozaar, Health Reform
Executive Summary
In buying Schering-Plough for $41.1 billion in March 2009, Merck aimed to lower its risk and build its product portfolio in the face of looming patent, reimbursement and pipeline challenges. A year after announcing plans for the merger, first-quarter results suggest that the company is keeping its promises
You may also be interested in...
Merck Names Ken Frazier President
The promotion moves Frazier one step closer to becoming CEO and Chairman when Dick Clark retires as expected next year.
Novo Nordisk's GLP-1 Victoza Off To A Good Start
New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.
With Isentress Sales Booming, New Integrase Inhibitors Step Up To The Plate
Merck's success with its HIV drug Isentress - the first and only integrase inhibitor on the market - and a recent shift in treatment guidelines that favor still greater use, are good signs for the emerging next-generation contenders in the class